MX387478B - Benzamidas sustituidas con 1,3-tiazol-2-ilo - Google Patents
Benzamidas sustituidas con 1,3-tiazol-2-iloInfo
- Publication number
- MX387478B MX387478B MX2020005909A MX2020005909A MX387478B MX 387478 B MX387478 B MX 387478B MX 2020005909 A MX2020005909 A MX 2020005909A MX 2020005909 A MX2020005909 A MX 2020005909A MX 387478 B MX387478 B MX 387478B
- Authority
- MX
- Mexico
- Prior art keywords
- thiazol
- compounds
- substituted benzamides
- prophylaxis
- disease
- Prior art date
Links
- -1 1,3-THIAZOL-2-YL Chemical group 0.000 title abstract 2
- 150000003936 benzamides Chemical class 0.000 title abstract 2
- 229940054066 benzamide antipsychotics Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001272 neurogenic effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Compuestos de benzamidas sustituidas con 1,3-tiazol-2-ilo de la fórmula general (I) que se describen y definen en la presente, con composiciones y combinaciones farmacéuticas que comprenden dichos compuestos y con el uso de dichos compuestos en la elaboración de una composición farmacéutica para el tratamiento o la profilaxis de una enfermedad, en particular de un trastorno neurogénico, ya sea como agente único o en combinación con otros ingredientes activos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14196954 | 2014-12-09 | ||
| PCT/EP2015/078765 WO2016091776A1 (en) | 2014-12-09 | 2015-12-07 | 1,3-thiazol-2-yl substituted benzamides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2020005909A MX2020005909A (es) | 2021-10-28 |
| MX387478B true MX387478B (es) | 2025-03-18 |
Family
ID=52015966
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017007658A MX377651B (es) | 2014-12-09 | 2015-12-07 | Benzamidas sustituidas con 1,3-tiazol-2-ilo. |
| MX2020005909A MX387478B (es) | 2014-12-09 | 2015-12-07 | Benzamidas sustituidas con 1,3-tiazol-2-ilo |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017007658A MX377651B (es) | 2014-12-09 | 2015-12-07 | Benzamidas sustituidas con 1,3-tiazol-2-ilo. |
Country Status (42)
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS63014B1 (sr) * | 2014-12-09 | 2022-04-29 | Bayer Ag | 1,3-tiazol-2-il supstituisani benzamidi |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| CN106588785A (zh) * | 2016-12-02 | 2017-04-26 | 山东吉田香料股份有限公司 | 一种乙酰基吡嗪的制备方法 |
| US10111883B1 (en) * | 2017-09-18 | 2018-10-30 | Bellus Health Cough Inc. | Selective P2X3 modulators |
| HU231206B1 (hu) | 2017-12-15 | 2021-10-28 | Richter Gedeon Nyrt. | Triazolobenzazepinek |
| MX2020012202A (es) | 2018-05-15 | 2021-01-29 | Bayer Ag | Benzamidas sustituidas con 1,3-tiazol-2-ilo para el tratamiento de enfermedades asociadas a la sensibilizacion de fibras nerviosas. |
| MX2020012230A (es) | 2018-05-15 | 2021-01-29 | Bayer Ag | Uso de benzamidas sustituidas con 1,3-tiazol-2-ilo para el tratamiento de enfermedades asociadas con la sensibilizacion de las fibras nerviosas. |
| AU2019353424B2 (en) | 2018-10-05 | 2022-12-08 | Shionogi & Co., Ltd. | Medicine for treating chronic cough |
| AU2019358327B2 (en) * | 2018-10-10 | 2025-04-24 | Glaxosmithkline Intellectual Property (No. 3) Limited | Treatment of pruritus with P2X3 antagonists |
| WO2020174283A1 (en) * | 2019-02-25 | 2020-09-03 | Bellus Health Cough Inc. | Treatment with p2x3 modulators |
| JOP20210272A1 (ar) * | 2019-04-05 | 2023-01-30 | Syngenta Crop Protection Ag | مركبات دايازين - أميد نشطة بشكل مبيد للآفات |
| BR112021020386A2 (pt) * | 2019-04-11 | 2021-12-07 | Syngenta Crop Protection Ag | Compostos de diazina-amida ativos pesticidamente |
| BR112021020279A2 (pt) | 2019-05-31 | 2021-12-14 | Chiesi Farm Spa | Derivados de piridopirimidinas como inibidores de p2x3 |
| BR112021022099A2 (pt) | 2019-05-31 | 2021-12-28 | Chiesi Farm Spa | Derivados de amino quinazolina como inibidores de p2x3 |
| EP3757103A1 (en) * | 2019-06-27 | 2020-12-30 | Bayer AG | Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide for the treatment of neurogenic diseases |
| CN113082023B (zh) * | 2019-12-23 | 2024-03-01 | 武汉朗来科技发展有限公司 | P2x3抑制剂和p2x4抑制剂的药物组合及其应用 |
| CN114072399B (zh) * | 2020-05-25 | 2024-11-29 | 中国医药研究开发中心有限公司 | 芳甲酰胺类化合物及其制备方法和医药用途 |
| WO2022063205A1 (zh) * | 2020-09-24 | 2022-03-31 | 中国医药研究开发中心有限公司 | 芳基甲酰胺类化合物及其制备方法和医药用途 |
| WO2022068930A1 (zh) * | 2020-09-30 | 2022-04-07 | 武汉人福创新药物研发中心有限公司 | 苯甲酰胺类化合物及其用途 |
| AU2021388923A1 (en) | 2020-11-27 | 2023-05-25 | Chiesi Farmaceutici S.P.A. | Amino quinazoline derivatives as p2x3 inhibitors |
| ES3023558T3 (en) | 2020-11-27 | 2025-06-02 | Chiesi Farm Spa | Phthalazine derivatives as p2x3 inhibitors |
| ES3026782T3 (en) | 2020-11-27 | 2025-06-12 | Chiesi Farm Spa | (aza)quinoline 4-amines derivatives as p2x3 inhibitors |
| CN114591317A (zh) * | 2020-12-04 | 2022-06-07 | 武汉人福创新药物研发中心有限公司 | P2x3抑制剂及其用途 |
| WO2022253945A1 (en) | 2021-06-04 | 2022-12-08 | Bayer Aktiengesellschaft | Pharmaceutical dosage forms comprising 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3r)-tetrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}-benzamide |
| WO2022253943A1 (en) | 2021-06-04 | 2022-12-08 | Bayer Aktiengesellschaft | Crystalline forms of 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3r)-tetrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}-benzamide |
| CN116396285A (zh) * | 2022-01-04 | 2023-07-07 | 上海华汇拓医药科技有限公司 | 氘代四氢呋喃类化合物制备及其应用 |
| US12024285B1 (en) | 2022-03-10 | 2024-07-02 | Skypad Tech, Inc. | Modular mobility system including thrusters movably connected to a support structure |
| US20250214986A1 (en) * | 2022-03-29 | 2025-07-03 | Humanwell Heathcare (Group) Co., Ltd. | P2x3 inhibitor compound, salt thereof, polymorph thereof and use thereof |
| CN118239941A (zh) * | 2022-12-22 | 2024-06-25 | 人福医药集团股份公司 | 制备p2x3抑制剂的方法 |
| WO2024240728A1 (en) | 2023-05-22 | 2024-11-28 | Chiesi Farmaceutici S.P.A. | Process and intermediates for the preparation of a p2x3 inhibitor |
| CN117777048B (zh) * | 2023-09-25 | 2024-09-20 | 上海科利生物医药有限公司 | 一种手性2-羟甲基吗啉-4-羧酸叔丁酯的制备方法 |
| WO2025140586A1 (zh) * | 2023-12-29 | 2025-07-03 | 人福医药集团股份公司 | 一种p2x3受体拮抗剂的固体分散体及其制备工艺 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006119504A2 (en) | 2005-05-04 | 2006-11-09 | Renovis, Inc. | Fused heterocyclic compounds, and compositions and uses thereof |
| WO2008000645A1 (en) | 2006-06-29 | 2008-01-03 | F. Hoffmann-La Roche Ag | Tetrazole-substituted arylamides |
| AU2007316681B2 (en) | 2006-11-09 | 2013-01-24 | F. Hoffmann-La Roche Ag | Thiazole and oxazole-substituted arylamides |
| US8501933B2 (en) * | 2006-11-09 | 2013-08-06 | Roche Palo Alto Llc | Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists |
| CA2682162C (en) | 2007-04-02 | 2016-05-10 | Renovis, Inc. | Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof |
| PL2139334T3 (pl) | 2007-04-17 | 2013-11-29 | Evotec Ag | Skondensowane związki heterocykliczne 2-cyjanofenylu i ich kompozycje i zastosowania |
| US20090099195A1 (en) | 2007-05-08 | 2009-04-16 | Astrazeneca Ab | Therapeutic Compounds 570 |
| TW200906826A (en) * | 2007-06-12 | 2009-02-16 | Genelabs Tech Inc | Anti-viral inhibitors and methods of use |
| WO2009058299A1 (en) | 2007-10-31 | 2009-05-07 | Merck & Co., Inc. | P2x3 receptor antagonists for treatment of pain |
| US8247401B2 (en) | 2007-10-31 | 2012-08-21 | Merck Sharp & Dohme Corp. | P2X3 receptor antagonists for treatment of pain |
| BR122018070508B8 (pt) | 2007-12-17 | 2021-07-27 | Hoffmann La Roche | derivados de arilamida triazol-substituída e seu uso |
| ES2570628T3 (es) | 2007-12-17 | 2016-05-19 | Hoffmann La Roche | Nuevas arilamidas con sustitución imidazol |
| DK2234976T3 (da) | 2007-12-17 | 2013-06-24 | Hoffmann La Roche | Nye pyrazol-substituerede arylamider |
| WO2009077371A1 (en) | 2007-12-17 | 2009-06-25 | F. Hoffmann-La Roche Ag | Tetrazole-substituted arylamide derivatives and their use as p2x3 and/or p2x2/3 purinergic receptor antagonists |
| MX2010009561A (es) * | 2008-02-29 | 2010-09-24 | Renovis Inc | Compuestos amida, composiciones y usos de los mismos. |
| JP5608655B2 (ja) | 2008-09-18 | 2014-10-15 | エヴォテック アーゲー | Ｐ２ｘ３受容体活性のモジュレーター |
| MX2011004570A (es) * | 2008-10-31 | 2011-06-17 | Merck Sharp & Dohme | Antagonistas del receptor p2x3 para el tratamiento del dolor. |
| KR101347958B1 (ko) | 2008-12-16 | 2014-02-14 | 에프. 호프만-라 로슈 아게 | 티아디아졸-치환된 아릴아미드 |
| ES2593405T3 (es) | 2009-06-22 | 2016-12-09 | F. Hoffmann-La Roche Ag | Nuevas arilamidas sustituidas por benzoxazolona |
| JP5476467B2 (ja) | 2009-06-22 | 2014-04-23 | エフ．ホフマン−ラ ロシュ アーゲー | 新規なビフェニルピリジンアミドおよびフェニルピリジンアミド |
| CN103221047B (zh) | 2010-01-13 | 2014-12-17 | 坦颇罗制药股份有限公司 | 化合物和方法 |
| WO2013009810A1 (en) | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| WO2013173441A2 (en) * | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| CA2884848C (en) | 2012-09-28 | 2017-08-22 | Pfizer Inc. | Benzamide and heterobenzamide compounds |
| ES2895225T3 (es) | 2013-01-31 | 2022-02-18 | Bellus Health Cough Inc | Compuestos de imidazopiridina y usos de los mismos |
| US10183937B2 (en) * | 2014-12-09 | 2019-01-22 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides |
| RS63014B1 (sr) * | 2014-12-09 | 2022-04-29 | Bayer Ag | 1,3-tiazol-2-il supstituisani benzamidi |
| MX2020012202A (es) | 2018-05-15 | 2021-01-29 | Bayer Ag | Benzamidas sustituidas con 1,3-tiazol-2-ilo para el tratamiento de enfermedades asociadas a la sensibilizacion de fibras nerviosas. |
| MX2020012230A (es) | 2018-05-15 | 2021-01-29 | Bayer Ag | Uso de benzamidas sustituidas con 1,3-tiazol-2-ilo para el tratamiento de enfermedades asociadas con la sensibilizacion de las fibras nerviosas. |
| EP3757103A1 (en) | 2019-06-27 | 2020-12-30 | Bayer AG | Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide for the treatment of neurogenic diseases |
-
2015
- 2015-12-07 RS RS20220250A patent/RS63014B1/sr unknown
- 2015-12-07 SI SI201531643T patent/SI3230281T1/sl unknown
- 2015-12-07 ES ES19181710T patent/ES2908822T3/es active Active
- 2015-12-07 PE PE2017000984A patent/PE20180227A1/es unknown
- 2015-12-07 SG SG10202012274RA patent/SG10202012274RA/en unknown
- 2015-12-07 CN CN201580075714.1A patent/CN107207507B/zh not_active Expired - Fee Related
- 2015-12-07 RS RS20211014A patent/RS62227B1/sr unknown
- 2015-12-07 CR CR20210108A patent/CR20210108A/es unknown
- 2015-12-07 PE PE2021001723A patent/PE20220253A1/es unknown
- 2015-12-07 JO JOP/2015/0301A patent/JOP20150301B1/ar active
- 2015-12-07 SI SI201531781T patent/SI3587417T1/sl unknown
- 2015-12-07 MX MX2017007658A patent/MX377651B/es active IP Right Grant
- 2015-12-07 JP JP2017530625A patent/JP6544665B2/ja not_active Expired - Fee Related
- 2015-12-07 EP EP19181710.5A patent/EP3587417B9/en active Active
- 2015-12-07 TN TN2017000244A patent/TN2017000244A1/en unknown
- 2015-12-07 PL PL19181710T patent/PL3587417T3/pl unknown
- 2015-12-07 HU HUE19181710A patent/HUE058009T2/hu unknown
- 2015-12-07 EA EA201891120A patent/EA034273B1/ru not_active IP Right Cessation
- 2015-12-07 DK DK19181710.5T patent/DK3587417T3/da active
- 2015-12-07 KR KR1020177018575A patent/KR102548799B1/ko active Active
- 2015-12-07 WO PCT/EP2015/078765 patent/WO2016091776A1/en not_active Ceased
- 2015-12-07 NZ NZ761161A patent/NZ761161A/en unknown
- 2015-12-07 HR HRP20220371TT patent/HRP20220371T1/hr unknown
- 2015-12-07 AU AU2015359626A patent/AU2015359626B2/en not_active Ceased
- 2015-12-07 ES ES15804824T patent/ES2882952T3/es active Active
- 2015-12-07 SG SG11201704717VA patent/SG11201704717VA/en unknown
- 2015-12-07 MX MX2020005909A patent/MX387478B/es unknown
- 2015-12-07 CR CR20170242A patent/CR20170242A/es unknown
- 2015-12-07 DK DK15804824.9T patent/DK3230281T3/da active
- 2015-12-07 MA MA41135A patent/MA41135B1/fr unknown
- 2015-12-07 US US15/534,855 patent/US10174016B2/en active Active
- 2015-12-07 BR BR112017012327-4A patent/BR112017012327B1/pt not_active IP Right Cessation
- 2015-12-07 PL PL15804824T patent/PL3230281T3/pl unknown
- 2015-12-07 MA MA50674A patent/MA50674B1/fr unknown
- 2015-12-07 PT PT158048249T patent/PT3230281T/pt unknown
- 2015-12-07 LT LTEP15804824.9T patent/LT3230281T/lt unknown
- 2015-12-07 UY UY0001036422A patent/UY36422A/es active IP Right Grant
- 2015-12-07 MY MYPI2017702127A patent/MY192690A/en unknown
- 2015-12-07 PT PT191817105T patent/PT3587417T/pt unknown
- 2015-12-07 EA EA201791261A patent/EA032312B1/ru not_active IP Right Cessation
- 2015-12-07 CN CN201910653985.0A patent/CN110256418B/zh not_active Expired - Fee Related
- 2015-12-07 HU HUE15804824A patent/HUE055290T2/hu unknown
- 2015-12-07 LT LTEP19181710.5T patent/LT3587417T/lt unknown
- 2015-12-07 CA CA2969952A patent/CA2969952A1/en active Pending
- 2015-12-07 KR KR1020237021217A patent/KR20230098368A/ko not_active Withdrawn
- 2015-12-07 EP EP15804824.9A patent/EP3230281B1/en active Active
- 2015-12-07 UA UAA201707107A patent/UA120382C2/uk unknown
- 2015-12-07 HR HRP20211002TT patent/HRP20211002T1/hr unknown
- 2015-12-07 CU CU2017000077A patent/CU24411B1/es unknown
- 2015-12-08 TW TW110100512A patent/TWI780562B/zh not_active IP Right Cessation
- 2015-12-08 TW TW104141168A patent/TWI716371B/zh not_active IP Right Cessation
- 2015-12-09 AR ARP150104007A patent/AR102948A1/es unknown
-
2017
- 2017-06-05 IL IL25266517A patent/IL252665B/en active IP Right Grant
- 2017-06-08 PH PH12017501079A patent/PH12017501079A1/en unknown
- 2017-06-09 CL CL2017001488A patent/CL2017001488A1/es unknown
- 2017-06-09 DO DO2017000137A patent/DOP2017000137A/es unknown
- 2017-06-09 CO CONC2017/0005742A patent/CO2017005742A2/es unknown
- 2017-06-09 SV SV2017005461A patent/SV2017005461A/es unknown
- 2017-06-09 EC ECIEPI201736253A patent/ECSP17036253A/es unknown
- 2017-06-09 NI NI201700073A patent/NI201700073A/es unknown
- 2017-11-21 US US15/820,429 patent/US10202369B2/en active Active
-
2018
- 2018-08-08 DO DO2018000182A patent/DOP2018000182A/es unknown
- 2018-11-13 JP JP2018212898A patent/JP6647371B2/ja not_active Expired - Fee Related
- 2018-11-15 US US16/192,314 patent/US10472354B2/en active Active
-
2019
- 2019-09-19 IL IL269467A patent/IL269467B/en active IP Right Grant
- 2019-09-19 IL IL269468A patent/IL269468B/en active IP Right Grant
- 2019-09-25 IL IL269661A patent/IL269661B/en active IP Right Grant
- 2019-10-01 US US16/589,838 patent/US11142523B2/en not_active Expired - Fee Related
-
2020
- 2020-06-07 IL IL275183A patent/IL275183B/en active IP Right Grant
- 2020-08-13 AR ARP200102296A patent/AR119761A2/es not_active Application Discontinuation
-
2021
- 2021-06-14 IL IL283979A patent/IL283979B/en unknown
- 2021-08-20 CY CY20211100750T patent/CY1124486T1/el unknown
- 2021-09-09 US US17/470,459 patent/US20230053411A1/en not_active Abandoned
-
2022
- 2022-03-15 CY CY20221100217T patent/CY1125083T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX387478B (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| PH12021550792A1 (en) | 2-(morpholin-4-yl)-1,7-naphthyridines | |
| EA201691590A1 (ru) | Бензимидазол-2-амины в качестве ингибиторов midhi | |
| UY35492A (es) | Compuestos novedosos | |
| PH12016501807A1 (en) | Novel compounds | |
| PH12017501133A1 (en) | Pyrazolopyridinamines | |
| MX378164B (es) | Amidas aromaticas de acido carboxilico. | |
| PH12016501814A1 (en) | Inhibitors of the wnt signalling pathways | |
| MA39762A (fr) | Nouveaux composés |